Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
LOS ANGELES, CA / ACCESSWIRE / April 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutic
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
02:41pm, Wednesday, 03'rd Apr 2024
Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.
Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
11:57am, Wednesday, 03'rd Apr 2024
Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despit
LOS ANGELES, CA / ACCESSWIRE / April 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutic
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback
09:08am, Tuesday, 02'nd Apr 2024
Verve Therapeutics Inc. shares VERV, -3.69% dropped 35% premarket on Tuesday after the company paused enrollment in a clinical trial of its gene-editing treatment for heart disease.
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
07:30am, Tuesday, 02'nd Apr 2024
Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-r
3 Stocks That Could Be the Next Big Thing in Gene Editing
04:19pm, Thursday, 21'st Mar 2024
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
04:08pm, Monday, 19'th Feb 2024
Biotech stocks, namely those involved with gene editing, have been explosive. Just look at CRISPR Therapeutics (NASADQ: CRSP ), for example.
3 Gene Editing Stocks With Unprecedented Surge Potential
06:05am, Tuesday, 13'th Feb 2024
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
12:28pm, Wednesday, 31'st Jan 2024
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
7 Mighty Healthcare Stocks Changing the Game of Medicine
12:04pm, Wednesday, 17'th Jan 2024
With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma
3 Stocks to Buy in the Booming Field of Gene Editing
04:38pm, Thursday, 11'th Jan 2024
The promise of gene editing is moving closer to being a reality. If you're an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene edi
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
06:30am, Tuesday, 02'nd Jan 2024
BOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing med
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade
01:32pm, Friday, 29'th Dec 2023
Verve Therapeutics (VERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
